RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRNA)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports (Cambridge) Jg. 8; H. 5; S. 1475 - 1483
Hauptverfasser:	Lamba, Simona, Russo, Mariangela, Sun, Chong, Lazzari, Luca, Cancelliere, Carlotta, Grernrum, Wipawadee, Lieftink, Cor, Bernards, Rene, Di Nicolantonio, Federica, Bardelli, Alberto
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 11.09.2014 Elsevier
Schlagworte:	Antineoplastic Agents - pharmacology Apoptosis Benzimidazoles - pharmacology Cell Line, Tumor Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Humans MAP Kinase Signaling System Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinase Kinases - genetics Mitogen-Activated Protein Kinase Kinases - metabolism Mutation Protein Kinase Inhibitors - pharmacology Protein Multimerization Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins p21(ras) raf Kinases - antagonists & inhibitors raf Kinases - genetics raf Kinases - metabolism ras Proteins - genetics ras Proteins - metabolism
ISSN:	2211-1247, 2211-1247
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!